Adam Wyden
Analyst · ADW Capital. Your line is now open.
Good. And then my last question is around M&A. I'm not sure if you called out what the ARR contribution is for MENU or what you'd expect it to do. But, obviously, we're in this kind of logjam, where private companies are in general, or at least historically traded at higher multiples of ARR, relative to the public comps you've seen, Vista and Thoma Bravo, you saw Avalara last week. Companies are out there buying, I mean, just to use Avalara as an example, I think they paid 11 times ARR, 12 times or something, when you do fully diluted and options, blah, blah, blah. And, that business was probably later in its maturity and had -- it's probably a lower similar growth rate to kind of Brink in all the rest. And so, I look at, par today, and I think it's, obviously it's definitely material undervalued to that. But, the question is, is when you look at private equity, they are taking advantage of what I would call the $30 million, $40 million of kind of cost of being public, not just the New York Stock Exchange listing costs, not just the comptroller CEO, CFO, blah, blah, blah, but also just kind of the systems in place and we’ve kind of benchmarked it and for a company of the scale, we think it could be $20mi, $30 million, $40 million of kind of duplicative costs. And there are obviously some public company players like Agilisys, like, Olo, like Transact Technologies, There are companies out there that might not have the same valuations as the private markets, where you could effectively do a transformational deal like Punchh in the public markets and kind of, get that scale and duplicative cost and kind of, synergy value. I mean how do you think about kind of going after companies like that or in the absence of private market deals that makes sense, kind of, doing something in the public markets, where you can, kind of, take advantage of the dislocation there.